|
San Leandro, CA, June 5, 2002 --
SAN LEANDRO, Calif.--(BW HealthWire)--June 5, 2002--Sepragen Corporation (OTC
BB: SPGNA - News),
a provider of patented technology and equipment for purification needs in the
biotech and nutraceutical industries, today announced the launch of the
QuantaSep 5000 Chromatography System. The QuantaSep 5000 is a totally automated
system that enables a biotech company to run at flow rates of 5 liters per
minute and produce 10 grams to 100 grams of product for clinical trials and
manufacturing. The system is a direct scale-up of the QuantaSep bench-scale
purification systems, which currently range in size from 100 to 1800 mls per
minute.
Said Mr. Vinit Saxena, Sepragen's CEO, "The QuantaSep 5000 allows a
biotech company to add productive capacity at 25% of the footprint requirement
of currently available systems. This enables a company to better utilize its
existing facilities, and ramp up manufacturing capacity without investment of
time and resources in new facility construction and approval. The
state-of-the-art graphical dashboard enables easy operation with a high level of
reliability along with automated FDA compliant report generation, even by lesser
skilled production staff." Continued Mr. Saxena, "Our continued focus
on using our proprietary technologies to solve urgent manufacturing and scale-up
issues by providing the industry with a 4-fold productive capacity advantage in
space and manpower utilization is receiving notice. Major companies, such as
Schering-Plough, Berlex, Human Genome Sciences and others have already adopted
the QuantaSep platform for development and scale-up and others are expected to
follow."
Sepragen is a leading supplier of separation process technology, equipment
and consumables to the biotechnology industry. In addition to its biotech drug
separation business, the Company has developed patented applications that
provide large market opportunities in the food and beverage industry, including
debittering citrus juices, extracting isoflavone (plant estrogen) from soy as
well as extracting proteins from whey. The Company holds over 14 issued patents
relating to its core technology.
<Back
The statements in this release that relate to future events or
performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
